BSX vs ISRG

• BSXBuy moresales growth, past year8.9%

  Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year.

• ISRGBuy more19%

  Intuitive Surgical's report on Oct 20 beat profit forecasts by 19%, and its sales grew 20% over the past year.

Percent return

• BSX−55.97%
• ISRG−21.43%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

ISRG leads on 4 of 6

BSXISRG

• Company size: BSX $68.5B, ISRG $127B.
  $68.5BCompany sizebigger$127B
• Sales growth, 1 yr: BSX +8.9%, ISRG +20%. ISRG is ahead.
  +8.9%Sales growth, 1 yr+20%
• Price for $1 of next year's profit: BSX $14, ISRG $38. BSX is ahead.
  $14cheaperPrice for $1 of next year's profit$38
• Profit per $1 of sales: BSX 20¢, ISRG 32¢. ISRG is ahead.
  20¢Profit per $1 of sales32¢
• Cash minus debt: BSX −$11.3B, ISRG +$4.04B. ISRG is ahead.
  −$11.3BCash minus debt+$4.04B
• Price change, 1 yr: BSX −56%, ISRG −21%. ISRG is ahead. S&P 500 +12%.
  −56%Price change, 1 yr−21%
• How much the price swings: BSX 37%, ISRG 46%. BSX is ahead.
  37%steadierHow much the price swings46%

Measure	BSXBoston Scientific	ISRGIntuitive Surgical
Price and returns
Price	$45.15	$449.58
Today	Best in this row: +1.00%	−0.10%
1 month	+5.62%	Best in this row: +6.03%
3 months	−11.81%	Best in this row: +12.05%
This year	−52.67%	Best in this row: −20.63%
1 year	−55.97%	Best in this row: −21.43%
5 years	+7.55%	Best in this row: +28.15%
From 52-week high	−57.0%	−24.2%
How much it swings (90 days)	Best in this row: 37%	46%
Valuation
Market value	$68.5B	$127B
Price vs last year's earnings	Best in this row: 19.3×	40.5×
Price vs next year's expected earnings	Best in this row: 13.9×	37.5×
Price vs earnings, adjusted for growth	Best in this row: 1.12×	2.34×
Price to sales	Best in this row: 2.9×	13.6×
Price vs cash it brings in	Best in this row: 18.6×	43.6×
Company value vs operating profit	Best in this row: 13.2×	34.2×
Growth
Revenue growth, 1 year	+8.9%	Best in this row: +20.4%
Revenue growth a year, last 3 years	+16.5%	Best in this row: +17.4%
Earnings per share growth, last year	Best in this row: +74.4%	+20.4%
Earnings per share growth expected next year	−1.1%	Best in this row: +10.9%
Profitability
Kept from sales after making the product	Best in this row: 68.0%	66.6%
Kept as operating profit	19.6%	Best in this row: 31.7%
Kept as final profit	16.6%	Best in this row: 25.5%
Kept as spare cash	15.8%	Best in this row: 31.1%
Profit on shareholders' money	14.1%	Best in this row: 17.9%
Profit on all money put in	10.6%	Best in this row: 24.0%
Balance sheet
Net cash (cash minus debt)	−$11.3B	Best in this row: $4.04B
Debt for each $1 of shareholders' money	0.46×	–
Short-term assets per $1 of bills due	1.36×	Best in this row: 3.33×
Our readPro
Our call	Buy more	Buy more
Why	Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year.	Intuitive Surgical's report on Oct 20 beat profit forecasts by 19%, and its sales grew 20% over the past year.
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	Best in this row: 73	66
Our value score	Best in this row: 96	38
Our growth score	76	Best in this row: 76
Our quality score	75	Best in this row: 83
Our price trend score	50	Best in this row: 62
Earnings and analysts
Analyst consensus	Buy	Buy
To average analyst target	+10.9%	Best in this row: +12.2%
Average analyst target	$50.05	$504.22
Analysts rating it a buy	61%	Best in this row: 77%
Buy ratings added, 3 months	−7	Best in this row: +2
Analysts covering	22	19

ISRG: faster sales growth and wider profit margins

Our pick of these: Intuitive Surgical

Buy more64/100

Sales growth +20.4% vs +8.9%

BSX +8.9%, ISRG +20.4%.

BSX+8.9%

ISRG+20.4%

Keeps 31.7% of sales as operating profit, vs 19.6%

BSX 19.6%, ISRG 31.7%.

BSX19.6%

ISRG31.7%

1-year return −21.4% vs −56.0%, S&P 500 +12.4%

BSX −56.0%, ISRG −21.4%.

BSX−56.0%

ISRG−21.4%

Where it loses: BSX has a lower P/E per point of growth, 1.56 vs 1.83

• 2ndBSXBuy more36/100Would need faster sales growth, +8.9% vs +20.4%

Prices as of yesterday, 3:59 PM ET. A view, not advice.